Cadrenal Therapeutics, Inc. operates as a biotech company. The Company focuses on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation. Cadrenal Therapeutics serves customers worldwide.

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cadrenal Therapeutics (CVKD US)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B5 | Prospectus

424B3 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)